Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Bicycle rapeutics

Important Biotech Catalysts For September 7, 2022 - End Of The Day Summary

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6 or PF-06760805 for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. Pfizer shares traded in a…

Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022

Benzinga's Top Ratings Upgrades, Downgrades For August 31, 2022

Bicycle Therapeutics's Return On Capital Employed Overview

Bicycle Therapeutics's Return On Capital Employed Overview

Benzinga Pro data, Bicycle Therapeutics (NASDAQ:BCYC) reported Q1 sales of $3.86 million. Earnings fell to a loss of $27.56 million, resulting in a 52.82% decrease from last quarter.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Analyst Ratings for Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings within the last quarter:

Expert Ratings for Bicycle Therapeutics

Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:

Recap: Bicycle Therapeutics Q1 Earnings

Bicycle Therapeutics (NASDAQ:BCYC) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

B. Riley Securities Downgrades Rating to Neutral for Bicycle Therapeutics, Lowers Price Target To $33

B. Riley Securities downgraded its rating of Bicycle Therapeutics (NASDAQ:BCYC) to Neutral with a price target of $33.00, changing its price target from $62.00 to $33.00. Shares of Bicycle Therapeutics are trading down 5.7% over the last 24 hours, at $23.48 per share.

inkl

Read news from The Economist, FT, and more,
with one subscription

Where Bicycle Therapeutics Stands With Analysts

Where Bicycle Therapeutics Stands With Analysts

Within the last quarter, Bicycle Therapeutics (NASDAQ:BCYC) has observed the following analyst ratings:

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

Bicycle Therapeutics's Return On Capital Employed Overview

Bicycle Therapeutics's Return On Capital Employed Overview

Bicycle Therapeutics (NASDAQ:BCYC) brought in sales totaling $3.77 million during Q4 according to data provided by Benzinga Pro. However, earnings decreased 22.88%, resulting in a loss of $18.04 million.

Organisations

European Commission

Intuitive Surgical

CrowdStrike Holdings

B of A Securities

PayPal Holdings

Coinbase Global

Robinhood Markets

Apollo Global Management

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play